MYO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

10.40M

-13.8%

-0.086

+760%

10.78M

+9.61%

-0.083

+3.13%

11.19M

+15.96%

-0.077

-29.55%

Estimates Revision

The market is revising No Change the revenue expectations for Myomo, Inc. (MYO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.50%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-8.50%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast MYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYO is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 10.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

6.50

High

10.50

Current: 0.000

Low

4.00

Averages

6.50

High

10.50

H.C. Wainwright

Buy

downgrade

2025-08-12

Reason

H.C. Wainwright

Price Target

2025-08-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Myomo to $5 from $9.50 and keeps a Buy rating on the shares. The firm says that while the company's Q2 ended well, there are warning signs ahead as Myomo reported that the number of patients added to its pipeline was significantly lower than expected.

Alliance Global Partners

Buy

maintain

2025-06-26

Reason

Alliance Global Partners

Price Target

2025-06-26

maintain

Buy

Reason

Alliance Global Partners lowered the firm's price target on Myomo to $6.50 from $6.75 and keeps a Buy rating on the shares following the analyst day. The firm cites minor reductions in its revenue forecast for the target trim but remains confident in the positive fundamental progress of the company.

Craig-Hallum

Buy

downgrade

$10 -> $8

2025-06-23

Reason

Craig-Hallum

Price Target

$10 -> $8

2025-06-23

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on Myomo to $8 from $10 and keeps a Buy rating on the shares following the company's investor day. Management outlined a target of $100M in revenue by 2028, notes the analyst, who is moderating the firm's 2025 revenue estimate to account for the potential for a slower recovery in cost-per-pipeline add. However, weakness in the shares is "overdone" given the company's strong growth and long-term growth potential, the analyst added.

Craig-Hallum

Buy

downgrade

$11 -> $10

2025-05-08

Reason

Craig-Hallum

Price Target

$11 -> $10

2025-05-08

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on Myomo to $10 from $11 and keeps a Buy rating on the shares following a mixed Q1 update. Q2 guidance disappointed, with revenue expected between $9.0M-$9.5M versus Street expectations of $10.9M.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$9 → $11

2025-03-17

Reason

Ascendiant Capital

Edward Woo

Price Target

$9 → $11

2025-03-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Sean Lee

Strong Buy

Maintains

$7.5 → $9.5

2025-03-12

Reason

HC Wainwright & Co.

Sean Lee

Price Target

$7.5 → $9.5

2025-03-12

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Myomo Inc (MYO.A) is -3.16, compared to its 5-year average forward P/E of -11.87. For a more detailed relative valuation and DCF analysis to assess Myomo Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.87

Current PE

-3.16

Overvalued PE

1.72

Undervalued PE

-25.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-12.67

Current EV/EBITDA

-3.79

Overvalued EV/EBITDA

9.56

Undervalued EV/EBITDA

-34.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.52

Current PS

0.85

Overvalued PS

4.18

Undervalued PS

0.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MYO News & Events

Events Timeline

No data

News

6.5

01-08Benzinga

Myomo, Inc. Activist Investor Pushes Governance Changes

7.0

2025-11-10SeekingAlpha

Myomo reaffirms its revenue goal of $40M–$42M for 2025, fueled by growth in the O&P channel and MyoConnect.

3.0

2025-11-09SeekingAlpha

Myomo's Earnings Forecast for Q3 2025

People Also Watch

Frequently Asked Questions

What is Myomo Inc (MYO) stock price today?

The current price of MYO is 0.9882 USD — it has increased 0.82 % in the last trading day.

What is Myomo Inc (MYO)'s business?

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.

What is the price predicton of MYO Stock?

What is Myomo Inc (MYO)'s revenue for the last quarter?

Myomo Inc revenue for the last quarter amounts to 10.09M USD, increased 9.59 % YoY.

What is Myomo Inc (MYO)'s earnings per share (EPS) for the last quarter?

Myomo Inc. EPS for the last quarter amounts to -0.09 USD, increased 200.00 % YoY.

What changes have occurred in the market's expectations for Myomo Inc (MYO)'s fundamentals?

How many employees does Myomo Inc (MYO). have?

Myomo Inc (MYO) has 184 emplpoyees as of January 10 2026.

What is Myomo Inc (MYO) market cap?

Today MYO has the market capitalization of 37.98M USD.